Publications

2025

2024

Murray JC, Sivapalan L, Hummelink K, Balan A, White JR, Niknafs N, Rhymee L, Pereira G, Rao N, Weksler B, Bahary N, Phallen J, Leal A, Bartlett DL, Marrone KA, Naidoo J, Goel A, Levy B, Rosner S, Hann CL, Scott SC, Feliciano J, Lam VK, Ettinger DS, Li QK, Illei PB, Monkhorst K, Scharpf RB, Brahmer JR, Velculescu VE, Zaidi AH, Forde PM, Anagnostou V.  Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer.  Clinical Cancer Research. 2024 Jan 17;30(2):389-403.  doi: 10.1158/1078-0432.CCR-23-1469. PMID: 37939140.  Article

2023

van ‘t Erve I, Medina JE, Leal A, Papp E, Phallen J, Adleff V, Chiao EJ, Arun AS, Bolhuis K, Simmons JK, Karandikar A, Valkenburg KC, Sausen M, Angiuoli SV, Scharpf RB, Punt CJA, Meijer GA, Velculescu VE, Fijneman RJA.  Metastatic colorectal cancer treatment response evaluation by ultra-deep sequencing of cell-free DNA and matched white blood cells.  Clinical Cancer Research. 2023 Mar 1;29(5):899-909. doi: 10.1158/1078-0432.CCR-22-2538.  PMID: 3653449.  Article

Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, Levy B, Feliciano J, Hann CL, Lam V, Pardoll DM, Karchin R, Seiwert TY, Brahmer JR, Forde PM, Velculescu VE, Anagnostou V.  Persistent mutation burden drives sustained anti-tumor immune responses.  Nature Medicine. 2023 Feb;29(2):440-449. PMID: 36702947.  Article

Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-Kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, Jänne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Gainor JF. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics. 2023 May;55(5):807-819. PMID: 37024582.  Article

Sivapalan L, Iams WT, Belcaid Z, Scott SC, Niknafs N, Balan A, White JR, Kopparapu P, Cann C, Landon BV, Pereira G, Velculescu VE, Hann CL, Lovly CM, Anagnostou V.  Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer.  Clinical Cancer Research. 2023 Jun 13;29(12):2310-2323. PMID: 37071497.  Article

Kim ES, Scharpf RB, Garcia-Closas M, Visvanathan K, Velculescu VE, Chatterjee N.  Potential utility of risk stratification for multicancer screening with liquid biopsy tests.  NPJ Precision Oncology. 2023 Apr 22;7(1):39. PMID: 37087533.  Article

Leal AIC, Mathios D, Jakubowski D, Johansen JS, Lau A, Wu T, Cristiano S, Medina JE, Phallen J, Bruhm DC, Carey J, Dracopoli NC, Bojesen SE, Scharpf RB, Velculescu VE, Vachani A, Bach PB.  Cell-Free DNA Fragmentomes in the Diagnostic Evaluation of Patients With Symptoms Suggestive of Lung Cancer.  Chest. 2023 Oct;164(4):1019-1027. PMID: 37116747.  Article

Shao XM, Huang J, Niknafs N, Balan A, Cherry C, White J, Velculescu VE, Anagnostou V, Karchin R.  Corrigendum to “HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade”.  Annals Oncology. 2023 Jul;34(7):634. PMID: 37121856.  Article

Ferrari AJ, Rawat P, Rendulich HS, Annapragada AV, Kinose Y, Zhang X, Devins K, Budina A, Scharpf RB, Mitchell MA, Tanyi JL, Morgan MA, Schwartz LE, Soong TR, Velculescu VE, Drapkin R.  H2Bub1 loss is an early contributor to clear cell ovarian cancer progression.  JCI Insight. 2023 Jun 22;8(12):e164995. PMID: 37345659.  Article

Topper MJ, Anagnostou V, Marrone KA, Velculescu VE, Jones PA, Brahmer JR, Baylin SB, Hostetter GH.  Derivation of CD8+ T cell infiltration potentiators in non-small-cell lung cancer through tumor microenvironment analysis.  iScience. 2023 Jun 10;26(7):107095.  PMID: 37456850.  Article

Bruhm DC, Mathios D, Foda ZH, Annapragada AV, Medina JE, Adleff V, Chiao EJ, Ferreira L, Cristiano S, White JR, Mazzilli SA, Billatos E, Spira A, Zaidi AH, Mueller J, Kim AK, Anagnostou V, Phallen J, Scharpf RB, Velculescu VE.  Single-molecule genome-wide mutation profiles of cell-free DNA for non-invasive detection of cancer.  Nature Genetics. 2023 Aug;55(8):1301-1310.  PMID: 37500728.  Article | Press

2022

Brown S, Lavery JA, Shen R, Martin AS, Kehl KL, Sweeney SM, Lepisto EM, Rizvi H, McCarthy CG, Schultz N, Warner JL, Park BH, Bedard PL, Riely GJ, Schrag D, Panageas KS; AACR Project GENIE Consortium.  Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.  JAMA Oncology. 2022 Feb 1;8(2):287-291. PMID: 34734967.  Article

Shao XM, Huang J, Niknafs N, Balan A, Cherry C, White J, Velculescu VE, Anagnostou V, Karchin R.  HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.  Annals Oncology. 2022 Jul;33(7):728-738.  PMID: 35339648.  Article

Keefer LA, White JR, Wood DE, Gerding KMR, Valkenburg KC, Riley D, Gault C, Papp E, Vollmer CM, Greer A, Hernandez J, McGregor PM 3rd, Zingone A, Ryan BM, Deak K, McCall SJ, Datto MB, Prescott JL, Thompson JF, Cerqueira GC, Jones S, Simmons JK, McElhinny A, Dickey J, Angiuoli SV, Diaz LA Jr, Velculescu VE, Sausen M.  Automated next-generation profiling of genomic alterations in human cancers.  Nature Communications. 2022 May 20;13(1):2830. PMID: 35595835.  Article

Hwang M, Canzoniero JV, Rosner S, Zhang G, White JR, Belcaid Z, Cherry C, Balan A, Pereira G, Curry A, Niknafs N, Zhang J, Smith KN, Sivapalan L, Chaft JE, Reuss JE, Marrone K, Murray JC, Li QK, Lam V, Levy BP, Hann C, Velculescu VE, Brahmer JR, Forde PM, Seiwert T, Anagnostou V.  Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy.  J Immunotherapy Cancer. 2022 Jun;10(6):e004688. PMID: 3568855.  Article

Botsis T, Murray J, Leal A, Palsgrove D, Wang W, White JR, Velculescu VE; Johns Hopkins Molecular Tumor Board Investigators; Anagnostou V.  Natural Language Processing Approaches for Retrieval of Clinically Relevant Genomic Information in Cancer.  Stud Health Technol Inform. 2022 Jun 29;295:350-353. PMID: 3577388.  Article

Mathios D, Bach PB, Phallen JA, Scharpf RB, Velculescu VE.  Reply to: Limitations of molecular testing in combination with computerized tomographic for lung cancer screening.  Nature Communications. 2022 Jul 8;13(1):3892. PMID: 35803904.  Article

Van Egeren D, Kohli K, Warner JL, Bedard PL, Riely G, Lepisto E, Schrag D, LeNoue-Newton M, Catalano P, Kehl KL, Michor F; AACR Project GENIE Consortium represented by Shawn Sweeney.  Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis.  Scientific Reports. 2022 Nov 9;12(1):19055. PMID: 36351964.  Article

2021

Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL Jr, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A.  Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.  Cancer Cell. 2021 Jan 11;39(1):122. PMID: 33306984.  Article

Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH, Mog BJ, Hou W, Justesen S, Blosser R, Tam A, Anagnostou V, Cottrell TR, Guo H, Chan HY, Singh D, Thapa S, Dykema AG, Burman P, Choudhury B, Aparicio L, Cheung LS, Lanis M, Belcaid Z, El Asmar M, Illei PB, Wang R, Meyers J, Schuebel K, Gupta A, Skaist A, Wheelan S, Naidoo J, Marrone KA, Brock M, Ha J, Bush EL, Park BJ, Bott M, Jones DR, Reuss JE, Velculescu VE, Chaft JE, Kinzler KW, Zhou S, Vogelstein B, Taube JM, Hellmann MD, Brahmer JR, Merghoub T, Forde PM, Yegnasubramanian S, Ji H, Pardoll DM, Smith KN.  Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.  Nature. 2021 Aug;596(7870):126-132. PMID: 34290408.  Article

Kehl KL, Riely GJ, Lepisto EM, Lavery JA, Warner JL, LeNoue-Newton ML, Sweeney SM, Rudolph JE, Brown S, Yu C, Bedard PL, Schrag D, Panageas KS; American Association of Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Consortium.  Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer.  JAMA Network Open. 2021 Jul 1;4(7):e2117547. PMID: 34309669. Article

Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR, Bruhm DC, Niknafs N, Ferreira L, Adleff V, Chiao JY, Leal A, Noe M, White JR, Arun AS, Hruban C, Annapragada AV, Jensen SØ, Ørntoft MW, Madsen AH, Carvalho B, de Wit M, Carey J, Dracopoli NC, Maddala T, Fang KC, Hartman AR, Forde PM, Anagnostou V, Brahmer JR, Fijneman RJA, Nielsen HJ, Meijer GA, Andersen CL, Mellemgaard A, Bojesen SE, Scharpf RB, Velculescu VE.  Detection and characterization of lung cancer using cell-free DNA fragmentomes.  Nature Communications. 2021 Aug 20;12(1):5060. PMID: 34417454.  Article | Press

Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH, Mog BJ, Hou W, Justesen S, Blosser R, Tam A, Anagnostou V, Cottrell TR, Guo H, Chan HY, Singh D, Thapa S, Dykema AG, Burman P, Choudhury B, Aparicio L, Cheung LS, Lanis M, Belcaid Z, El Asmar M, Illei PB, Wang R, Meyers J, Schuebel K, Gupta A, Skaist A, Wheelan S, Naidoo J, Marrone KA, Brock M, Ha J, Bush EL, Park BJ, Bott M, Jones DR, Reuss JE, Velculescu VE, Chaft JE, Kinzler KW, Zhou S, Vogelstein B, Taube JM, Hellmann MD, Brahmer JR, Merghoub T, Forde PM, Yegnasubramanian S, Ji H, Pardoll DM, Smith KN.  Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.  Nature. 2021 Oct;598(7881):E1. PMID: 34608287.  Article

Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ, Borghaei H, Lanis M, Belcaid Z, Smith KN, Balan A, White JR, Cherry C, Ashok Sivakumar IK, Shao XM, Chan HY, Singh D, Thapa S, Illei PB, Pardoll DM, Karchin R, Velculescu VE, Brahmer JR, Ramalingam SS.  Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.  Nature Medicine. 2021 Nov;27(11):1910-1920. PMID: 34750557.  Article

van ‘t Erve I, Wesdorp NJ, Medina JE, Ferreira L, Leal A, Huiskens J, Bolhuis K, van Waesberghe JTM, Swijnenburg RJ, van den Broek D, Velculescu VE, Kazemier G, Punt CJA, Meijer GA, Fijneman RJA.  KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases.  JCO Precision Oncololgy. 2021 Nov 17;5:PO.21.00223. PMID: 34820593.  Article

2020

Zhang J, Ji Z, Caushi JX, El Asmar M, Anagnostou V, Cottrell TR, Chan HY, Suri P, Guo H, Merghoub T, Chaft JE, Reuss JE, Tam AJ, Blosser RL, Abu-Akeel M, Sidhom JW, Zhao N, Ha JS, Jones DR, Marrone KA, Naidoo J, Gabrielson E, Taube JM, Velculescu VE, Brahmer JR, Housseau F, Hellmann MD, Forde PM, Pardoll DM, Ji H, Smith KN. Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.  Clinical Cancer Research. 2020 Mar 15;26(6):1327-1337. PMID: 31754049.  Article

Shao XM, Bhattacharya R, Huang J, Sivakumar IKA, Tokheim C, Zheng L, Hirsch D, Kaminow B, Omdahl A, Bonsack M, Riemer AB, Velculescu VE, Anagnostou V, Pagel KA, Karchin R.  High-throughput prediction of MHC class I and class II neoantigens with MHCnuggets.  Cancer Immunology Research. 2020 Mar;8(3):396-408. PMID:  31871119.  Article

Leal A, van Grieken NCT, Palsgrove DN, Phallen J, Medina JE, Hruban C, Broeckaert MAM, Anagnostou V, Adleff V, Bruhm DC, Canzoniero JV, Fiksel J, Nordsmark M, Warmerdam FARM, Verheul HMW, van Spronsen DJ, Beerepoot LV, Geenen MM, Portielje JEA, Jansen EPM, van Sandick J, Meershoek-Klein Kranenbarg E, van Laarhoven HWM, van der Peet DL, van de Velde CJH, Verheij M, Fijneman R, Scharpf RB, Meijer GA, Cats A, Velculescu VE.  White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer.  Nature Communications. 2020 Jan 27;11(1):525. PMID: 31988276.  Article

Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, Medvedev S, Kinose Y, Devins K, Verma P, Ly K, Wang Y, Greenberg RA, Schwartz L, Johnson N, Scharpf RB, Mills GB, Zhang R, Velculescu VE, Brown EJ, Simpkins F.  Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.  Nature Communications. 2020 Jul 24;11(1):3726. PMID: 32709856.  Article

Noë M, Niknafs N, Fischer CG, Hackeng WM, Beleva Guthrie V, Hosoda W, Debeljak M, Papp E, Adleff V, White JR, Luchini C, Pea A, Scarpa A, Butturini G, Zamboni G, Castelli P, Hong SM, Yachida S, Hiraoka N, Gill AJ, Samra JS, Offerhaus GJA, Hoorens A, Verheij J, Jansen C, Adsay NV, Jiang W, Winter J, Albores-Saavedra J, Terris B, Thompson ED, Roberts NJ, Hruban RH, Karchin R, Scharpf RB, Brosens LAA, Velculescu VE, Wood LD.  Genomic characterization of malignant progression in neoplastic pancreatic cysts.  Nature Communications. 2020 Aug 14;11(1):4085. PMID: 32796935.  Article

Schraa SJ, van Rooijen KL, van der Kruijssen DEW, Rubio Alarcón C, Phallen J, Sausen M, Simmons J, Coupé VMH, van Grevenstein WMU, Elias S, Verkooijen HM, Laclé MM, Bosch LJW, van den Broek D, Meijer GA, Velculescu VE, Fijneman RJA, Vink GR, Koopman M; PLCRC-MEDOCC group.  Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.  BMC Cancer. 2020 Aug 20;20(1):790. PMID: 32819390.  Article

Esai Selvan M, Zauderer MG, Rudin CM, Jones S, Mukherjee S, Offit K, Onel K, Rennert G, Velculescu VE, Lipkin SM, Klein RJ, Gümüş ZH.  Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk.  J Thoracic Oncology. 2020 Dec;15(12):1871-1879. PMID: 32866655.  Article

Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL Jr, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A.  Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.  Cancer Cell. 2020 Oct 12;38(4):500-515.e3. PMID: 32916126.  Article

Reuss JE, Anagnostou V, Cottrell TR, Smith KN, Verde F, Zahurak M, Lanis M, Murray JC, Chan HY, McCarthy C, Wang D, White JR, Yang S, Battafarano R, Broderick S, Bush E, Brock M, Ha J, Jones D, Merghoub T, Taube J, Velculescu VE, Rosner G, Illei P, Pardoll DM, Topalian S, Naidoo J, Levy B, Hellmann M, Brahmer JR, Chaft JE, Forde PM.  Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.  J Immunotherapy Cancer. 2020 Sep;8(2):e001282. PMID: 32929052.  Article

van ‘t Erve I, Greuter MJE, Bolhuis K, Vessies DCL, Leal A, Vink GR, van den Broek D, Velculescu VE, Punt CJA, Meijer GA, Coupé VMH, Fijneman RJA.  Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.  J Molecular Diagnostics. 2020 Dec;22(12):1430-1437. PMID: 32961317.  Article

Anagnostou V, Bruhm DC, Niknafs N, White JR, Shao XM, Sidhom JW, Stein J, Tsai HL, Wang H, Belcaid Z, Murray J, Balan A, Ferreira L, Ross-Macdonald P, Wind-Rotolo M, Baras AS, Taube J, Karchin R, Scharpf RB, Grasso C, Ribas A, Pardoll DM, Topalian SL, Velculescu VE.  Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.  Cell Reports Medicine. 2020 Nov 17;1(8):100139. PMID: 33294860.  Article

2019

Iavarone C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Leverson JD, Sampath D, Mills GB, Brugge JS.  Combined MEK and BCL-2/XL inhibition is effective in high-grade serous ovarian cancer patient-derived xenograft models and BIM levels are predictive of responsiveness.  Molecular Cancer Therapeutics 18(3):642-655, 2019.  PMID:  30679390. Article

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F. Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.  J Immunotherapy Cancer. 2019 Feb 11;7(1):40. PMID: 30744692.  Article

Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C, Velculescu V et al.,; IBCD-Faculty. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology.  European J Cancer. 2019 Jun;114:128-136. PMID: 31060925.  Article

Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, Debeljak M, Kamiyama H, Narang A, Laheru DA, Zheng L, Lin MT, Gocke CD, Fishman EK, Hruban RH, Goggins MG, Molenaar IQ, Cameron JL, Weiss MJ, Velculescu VE, He J, Wolfgang CL, Eshleman JR.  Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.  Clinical Cancer Research. 2019 Aug 15;25(16):4973-4984. PMID: 31142500.  Article

Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE.  Genome-wide cell-free DNA fragmentation in patients with cancer.  Nature. 2019 Jun;570(7761):385-389. PMID: 31142840.  Article | Press

Mathios D, Hwang T, Xia Y, Phallen J, Rui Y, See AP, Maxwell R, Belcaid Z, Casaos J, Burger PC, McDonald KL, Gallia GL, Cope L, Kai M, Brem H, Pardoll DM, Ha P, Green JJ, Velculescu VE, Bettegowda C, Park CK, Lim M.  Genome-wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types.  International J Cancer. 2019 Dec 15;145(12):3425-3435. PMID: 31373686.  Article

Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, Triplett O, Mariño-Enríquez A, Wagner AJ, Demetri GD, Velculescu VE, Paweletz CP, Fletcher JA, George S.  Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors. Clinical Cancer Research. 2019 Dec 15;25(24):7287-7293. PMID: 31471313.  Article

Georgiadis A, Durham JN, Keefer LA, Bartlett BR, Zielonka M, Murphy D, White JR, Lu S, Verner EL, Ruan F, Riley D, Anders RA, Gedvilaite E, Angiuoli S, Jones S, Velculescu VE, Le DT, Diaz LA Jr, Sausen M.  Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade.  Clinical Cancer Research. 2019 Dec 1;25(23):7024-7034. PMID: 31506389.  Article